About
Hedgehog signaling pathway inhibitor
Areas of Focus
Categories
Small Molecule PharmaceuticalSan Diego & Southern California
Team (28)
Andrew Lam, PharmD
Endeavor BioMedicines
team_member
Anita DiFrancesco
Senior Vice President, Clinical Operations
Endeavor BioMedicines
executive
Bernard Davitian, MBA
Endeavor BioMedicines
team_member
Betsy Gelfand
Senior Vice President, Finance
Endeavor BioMedicines
executive
Chris Krueger, JD
Chief Operating Officer
Endeavor BioMedicines
executive
Cindy Wang, PhD
Endeavor BioMedicines
team_member
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
306
By Phase
PHASE2: 3PHASE1: 1
By Status
COMPLETED: 2RECRUITING: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06422884Lead Sponsor
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
PHASE2Recruiting
200 participants
Started: Nov 15, 2024 · Completed: Oct 31, 2026
NCT05817240Lead Sponsor
A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects
PHASE1Completed
21 participants
Started: May 3, 2023 · Completed: Jun 21, 2023
NCT05199584Lead Sponsor
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
PHASE2Active, not recruiting
44 participants
Started: May 24, 2022 · Completed: May 31, 2024
NCT04968574Lead Sponsor
A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
PHASE2Completed
41 participants
Started: Aug 26, 2021 · Completed: Nov 30, 2023
Locations (1)
Headquarters
San Diego, CA, United States
Map
Loading map...